French Genome Profiling Trial Points to Frequent Actionable Mutations in Advanced Cancer

Jun 03, 2017

|

CHICAGO (GenomeWeb) – Targeting actionable genetic mutations identified by tumor genomic profiling may slightly boost survival time in individuals with advanced cancer, though there are still challenges accessing molecularly tailored treatments for individuals with such mutations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Back for Another Round

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

Imprints Left Behind

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

Get the Most Out of It

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

Cell Papers Explore Translation, Messenger RNA Localization

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.

Featured White Papers

Cell Engineering 101

CRISPR 101

Gene Knockouts: How CRISPR Is Used to Inactivate Genes

BlueBee Data Security & Compliance

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu